IP Library Granted Patent US 7,265,099
Granted Patent B1
US 7,265,099 · App. 10/049,393 · Granted Sep 4, 2007

Use of chemical chelators as reversal agents for drug-induced neuromuscular block

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,265,099
App. No.
10/049,393
Granted
Sep 4, 2007
Kind
B1
Abstract

The invention relates to the use of chemical chelators for the preparation of a medicament for the reversal of drug-induced neuromuscular block, to a kit for providing neuromuscular block and its reversal, and to cyclophane derivatives having general formula (A) wherein R is (a), (b) or (c); or general formula (B) wherein X is (a), (b) or (d), or a pharmaceutically acceptable salt thereof.

Claims (3)

1. A method for reversal of drug-induced neuromuscular block in a patient caused by a clinically-used neuromuscular blocking agent which acts by reversible binding to the acetylcholine receptor, comprising parenterally administering to said patient an effective amount of γ-cyclodextrin or a derivative thereof capable of forming a guest-host complex with the neuromuscular blocking agent inducing the neuromuscular block in the patient, and which is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium and tubocurarine.

2. The method according to claim 1 , wherein the neuromuscular blocking agent is rocuronium or vecuronium.

3. A method for reversal of drug-induced neuromuscular block in a patient caused by a clinically-used neuromuscular blocking agent which acts by reversible binding to the acetylcholine receptor, comprising parenterally administering to said patient an effective amount of β-cyclodextrin or a derivative thereof capable of forming a guest-host complex with the neuromuscular blocking agent inducing the neuromuscular block in the patient, the neuromuscular blocking agent being rocuronium.

Assignments (3)
MERGER Recorded Mar 8, 2013
From: ORGANON BIOSCIENCES NEDERLAND B.V.
To: MERCK SHARP & DOHME B.V.
Reel/Frame 029940/0296 →
MERGER Recorded Mar 7, 2013
From: MSD OSS B.V.
To: ORGANON BIOSCIENCES NEDERLAND B.V.
Reel/Frame 029939/0001 →
MERGER Recorded Dec 1, 2011
From: N.V. ORGANON
To: MSD OSS B.V.
Reel/Frame 027307/0482 →